Role of advanced glycation end products in hypertension and cardiovascular risk: Human studies

Journal of the American Society of Hypertension

Volumn 6, Issue 6, 2012, Pages 427-435

  Baumann, Marcus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Advanced glycation end products (AGEs); blood pressure; large artery stiffness; microcirculation; N epsilon (carboxymethyl)lysine (CML); RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; LYSINE DERIVATIVE;

AMINO ACID BLOOD LEVEL; ARTERIAL STIFFNESS; ARTERY DIAMETER; CARBOHYDRATE ANALYSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; MICROCIRCULATION; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VEIN DIAMETER;

GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MICROCIRCULATION; RECEPTORS, IMMUNOLOGIC; RISK FACTORS; VASCULAR DISEASES;

EID: 84870425773     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2012.10.005     Document Type: Review

References (52)

1. A. Bierhaus, P.M. Humpert, D.M. Stern, B. Arnold, and P.P. Nawroth Advanced glycation end product receptor-mediated cellular dysfunction Ann N Y Acad Sci 1043 2005 676 680
2. E.D. Schleicher, E. Wagner, and A.G. Nerlich Increased accumulation of the glycoxidation product n(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging J Clin Invest 99 1997 457 468
3. J.L. Wautier, and A.M. Schmidt Protein glycation: a firm link to endothelial cell dysfunction Circ Res 95 2004 233 238
4. A. Bierhaus, P.M. Humpert, M. Morcos, T. Wendt, T. Chavakis, and B. Arnold Understanding rage, the receptor for advanced glycation end products J Mol Med (Berl) 83 2005 876 886
5. G. Basta, A.I. Corciu, A. Vianello, S. Del Turco, I. Foffa, and T. Navarra Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis Atherosclerosis 210 2010 614 618
6. P. Ehlermann, K. Eggers, A. Bierhaus, P. Most, D. Weichenhan, and J. Greten Increased proinflammatory endothelial response to s100a8/a9 after preactivation through advanced glycation end products Cardiovasc Diabetol 5 2006 6
7. G. Basta Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications Atherosclerosis 196 2008 9 21
8. L.A. Altwegg, M. Neidhart, M. Hersberger, S. Muller, F.R. Eberli, and R. Corti Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes Eur Heart J 28 2007 941 948
9. R.M. Narvaez-Rivera, A. Rendon, M.C. Salinas-Carmona, and A.G. Rosas-Taraco Soluble rage as a severity marker in community acquired pneumonia associated sepsis BMC Infect Dis 12 2012 15
10. T. Watanabe, K. Asai, H. Fujimoto, H. Tanaka, H. Kanazawa, and K. Hirata Increased levels of hmgb-1 and endogenous secretory rage in induced sputum from asthmatic patients Respir Med 105 2011 519 525
11. M.T. Schram, C.G. Schalkwijk, A.H. Bootsma, J.H. Fuller, N. Chaturvedi, and C.D. Stehouwer Advanced glycation end products are associated with pulse pressure in type 1 diabetes: The Eurodiab Prospective Complications Study Hypertension 46 2005 232 237
12. A. Benetos, M. Safar, A. Rudnichi, H. Smulyan, J.L. Richard, and P. Ducimetieere Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population Hypertension 30 1997 1410 1415
13. D. Geroldi, C. Falcone, E. Emanuele, A. D'Angelo, M. Calcagnino, and M.P. Buzzi Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension J Hypertens 23 2005 1725 1729
14. S. Sankaralingam, H. Xu, Y. Jiang, T. Sawamura, and S.T. Davidge Evidence for increased methylglyoxal in the vasculature of women with preeclampsia: role in upregulation of lox-1 and arginase Hypertension 54 2009 897 904
15. C. Feng, Y. Tao, T. Shang, and M. Yu Calprotectin, rage and TNF-alpha in hypertensive disorders in pregnancy: expression and significance Arch Gynecol Obstet 283 2011 161 166
16. K. Naruse, T. Sado, T. Noguchi, T. Tsunemi, S. Yoshida, and J. Akasaka Peripheral rage (receptor for advanced glycation endproducts)-ligands in normal pregnancy and preeclampsia: novel markers of inflammatory response J Reprod Immunol 93 2012 69 74
17. R.D. Semba, S.S. Najjar, K. Sun, E.G. Lakatta, and L. Ferrucci Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults Am J Hypertens 22 2009 74 79
18. M. McNulty, A. Mahmud, and J. Feely Advanced glycation end-products and arterial stiffness in hypertension Am J Hypertens 20 2007 242 247
19. A. Bierhaus, M.A. Hofmann, R. Ziegler, and P.P. Nawroth Ages and their interaction with age-receptors in vascular disease and diabetes mellitus. I. The age concept Cardiovasc Res 37 1998 586 600
20. B.P. Shapiro, T.E. Owan, S.F. Mohammed, D.M. Meyer, L.D. Mills, and C.G. Schalkwijk Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines Circulation 118 2008 1002 1010
21. A. Baidoshvili, H.W. Niessen, W. Stooker, R.A. Huybregts, C.E. Hack, and J.A. Rauwerda N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels Atherosclerosis 174 2004 287 292
22. M. Baumann, T. Richart, D. Sollinger, J. Pelisek, M. Roos, and T. Kouznetsova Association between carotid diameter and the advanced glycation endproduct nepsilon-carboxymethyllysine (cml) Cardiovasc Diabetol 8 2009 45
23. K. Mizutari, T. Ono, K. Ikeda, K. Kayashima, and S. Horiuchi Photo-enhanced modification of human skin elastin in actinic elastosis by n(epsilon)-(carboxymethyl)lysine, one of the glycoxidation products of the maillard reaction J Invest Dermatol 108 1997 797 802
24. J.K. Kim, S. Park, M.J. Lee, Y.R. Song, S.H. Han, and S.G. Kim Plasma levels of soluble receptor for advanced glycation end products (srage) and proinflammatory ligand for rage (en-rage) are associated with carotid atherosclerosis in patients with peritoneal dialysis Atherosclerosis 220 2012 208 214
25. S.J. Yang, S. Kim, S.Y. Hwang, T.N. Kim, H.Y. Choi, and H.J. Yoo Association between srage, esrage levels and vascular inflammation: Analysis with (18)f-fluorodeoxyglucose positron emission tomography Atherosclerosis 220 2012 402 406
26. M.P. Wautier, P. Massin, P.J. Guillausseau, M. Huijberts, B. Levy, and E. Boulanger N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients Diabetes Metab 29 2003 44 52
27. P.M. Humpert, S. Kopf, Z. Djuric, T. Wendt, M. Morcos, and P.P. Nawroth Plasma srage is independently associated with urinary albumin excretion in type 2 diabetes Diabetes Care 29 2006 1111 1113
28. K.C. Tan, S.W. Shiu, W.S. Chow, L. Leng, R. Bucala, and D.J. Betteridge Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes Diabetologia 49 2006 2756 2762
29. J.Y. Yu, X.F. An, J.S. Liu, S.C. Ten, X. Wang, and Y. Zhao Plasma srage is not associated with urinary microalbumin excretion in type 2 diabetic nephropathy at the early stage Diabetes Res Clin Pract 87 2010 157 160
30. J.W. Nin, I. Ferreira, C.G. Schalkwijk, M.H. Prins, N. Chaturvedi, J.H. Fuller Group EPCS Levels of soluble receptor for age are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: The Eurodiab Prospective Complications Study Diabetologia 52 2009 705 714
31. B.O. Boehm, S. Schilling, S. Rosinger, G.E. Lang, G.K. Lang, and R. Kientsch-Engel Elevated serum levels of n(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema Diabetologia 47 2004 1376 1379
32. M. Challier, S. Jacqueminet, O. Benabdesselam, A. Grimaldi, and J.L. Beaudeux Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes Clin Chem 51 2005 1749 1750
33. L. Southern, J. Williams, and M.M. Esiri Immunohistochemical study of n-epsilon-carboxymethyl lysine (cml) in human brain: relation to vascular dementia BMC Neurol 7 2007 35
34. B.I. Hudson, Y.P. Moon, A.Z. Kalea, M. Khatri, C. Marquez, and A.M. Schmidt Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: The Northern Manhattan Study (NOMAS) Atherosclerosis 216 2011 192 198
35. J.W. Hartog, A.A. Voors, C.G. Schalkwijk, J. Scheijen, T.D. Smilde, and K. Damman Clinical and prognostic value of advanced glycation end-products in chronic heart failure Eur Heart J 28 2007 2879 2885
36. J.W. Nin, A. Jorsal, I. Ferreira, C.G. Schalkwijk, M.H. Prins, and H.H. Parving Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study Diabetes Care 34 2011 442 447
37. B.K. Kilhovd, A. Juutilainen, S. Lehto, T. Ronnemaa, P.A. Torjesen, and K.I. Birkeland High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study Arterioscler Thromb Vasc Biol 25 2005 815 820
38. B.K. Kilhovd, A. Juutilainen, S. Lehto, T. Ronnemaa, P.A. Torjesen, and K.F. Hanssen Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study Diabetologia 50 2007 1409 1417
39. S.B. Schwedler, T. Metzger, R. Schinzel, and C. Wanner Advanced glycation end products and mortality in hemodialysis patients Kidney Int 62 2002 301 310
40. M. Busch, S. Franke, G. Wolf, A. Brandstadt, U. Ott, and J. Gerth The advanced glycation end product n(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension Am J Kidney Dis 48 2006 571 579
41. Z. Wagner, M. Molnar, G.A. Molnar, M. Tamasko, B. Laczy, and L. Wagner Serum carboxymethyllysine predicts mortality in hemodialysis patients Am J Kidney Dis 47 2006 294 300
42. H.M. Colhoun, D.J. Betteridge, P. Durrington, G. Hitman, A. Neil, and S. Livingstone Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the cards trial Diabetes 60 2011 2379 2385
43. R.A. Malik, S. Williamson, C. Abbott, A.L. Carrington, J. Iqbal, and W. Schady Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial Lancet 352 1998 1978 1981
44. Y. Saisho, N. Komiya, and H. Hirose Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan Diabetes Res Clin Pract 74 2006 201 203
45. F. Monacelli, A. Poggi, D. Storace, A. Durante, N. Traverso, and G.L. Viviani Effects of valsartan therapy on protein glycoxidation Metabolism 55 2006 1619 1624
46. J.W. Hartog, R.M. van de Wal, C.G. Schalkwijk, T. Miyata, W. Jaarsma, and H.W. Plokker Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction Eur J Heart Fail 12 2010 397 403
47. M. Busch, S. Franke, G. Wolf, R.D. Rohde, G. Stein Collaborative Study G Serum levels of the advanced glycation end products nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension Nephron Clin Pract 108 2008 c291 c297
48. F. Persson, P. Rossing, P. Hovind, C.D. Stehouwer, C. Schalkwijk, and L. Tarnow Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: An IRMA 2 substudy Diabetes 55 2006 3550 3555
49. S. Yamagishi, T. Matsui, K. Nakamura, M. Takeuchi, and H. Inoue Telmisartan inhibits advanced glycation end products (AGES)-elicited endothelial cell injury by suppressing age receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation Protein Pept Lett 15 2008 850 853
50. K. Nakamura, S. Yamagishi, Y. Nakamura, K. Takenaka, T. Matsui, and Y. Jinnouchi Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble rage in patients with essential hypertension Microvasc Res 70 2005 137 141
51. Y. Jinnouchi, S. Yamagishi, M. Takeuchi, S. Ishida, Y. Jinnouchi, and J. Jinnouchi Atorvastatin decreases serum levels of advanced glycation end products (AGES) in patients with type 2 diabetes Clin Exp Med 6 2006 191 193
52. F. Santilli, L. Bucciarelli, D. Noto, A.B. Cefalu, V. Davi, and E. Ferrante Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins Free Radic Biol Med 43 2007 1255 1262